Independent Data Monitoring Committee Finds Clear Efficacy for REGEN-COV™ (casirivimab with imdevimab) in Phase 3 COVID-19 Outpatient Outcomes Trial
Go back to Independent Data Monitoring Committee Finds Clear Efficacy for REGEN-COV™ (casirivimab with imdevimab) in Phase 3 COVID-19 Outpatient Outcomes Trial| Regeneron (NASDAQ: REGN) | Delayed: 803.90 +5.73 (0.72%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $798.17 | 52 Week High | $592.36 | |||
| Open | $802.48 | 52 Week Low | $325.35 | |||
| Day High | $811.66 | P/E | 211.00 | |||
| Day Low | $791.31 | EPS | $3.81 | |||
| Volume | 600,256 | |||||
